Global Schizophrenia Drugs Market

Global Schizophrenia Drugs Market Size, Share, Growth Analysis, By Therapeutic Class(Second Generation, Third Generation), By Treatment(Oral, Injectable), By Distribution channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031

Report ID: SQSG35I2011 | Region: Global | Published Date: April, 2024
Pages: 157 | Tables: 90 | Figures: 76

Global Schizophrenia Drugs Market News

  • In June 2022, Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced encouraging interim results from the first 100 patients in its world-first, international, six-week, open-label, randomized, rater-blinded, multi-center study of evenamide as an add-on to an antipsychotic in patients with moderate to severe treatment-resistant schizophrenia (TRS) who were not responding to current antipsychotic medication.
  • In April 2022, Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are prescribed worldwide and places Saladax in a premier position in the antipsychotic drug testing field.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Schizophrenia Drugs Market size was valued at USD 7.16 billion in 2019 and is poised to grow from USD 7.58 billion in 2023 to USD 12.58 billion by 2031, growing at a CAGR of 5.8% in the forecast period (2024-2031).

There is huge competition in the global Schizophrenia drugs Market. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and product differentiation are some of the growth strategies that are adopted by these key players to thrive in the competitive market. 'Otsuka Pharmaceutical', 'Johnson & Johnson', 'Eli Lilly and Company', 'AstraZeneca', 'Pfizer', 'Bristol-Myers Squibb', 'Allergan', 'Sumitomo Dainippon Pharma', 'Lundbeck', 'Alkermes', 'Vanda Pharmaceuticals', 'Intra-Cellular Therapies', 'ACADIA Pharmaceuticals', 'Sunovion Pharmaceuticals', 'Neurocrine Biosciences', 'Takeda Pharmaceutical', 'H. Lundbeck A/S', 'Recordati S.p.A.', 'Reviva Pharmaceuticals Inc.', 'Minerva Neurosciences Inc.'

The market is anticipated to be driven by an increase in the number of patients receiving treatment and a rising desire for better healthcare infrastructure. In recent years, governments in multiple nations have worked successfully with numerous hospitals to provide better safety for those who suffer from schizophrenia. The market under study is expanding as a result of the growing illness load and the growing need to properly control it.

The mechanisms behind schizophrenia, which were formerly considered to be related to excessive presynaptic dopamine in certain parts of the brain, are now known to be far more complicated, involving structural and chemical abnormalities throughout brain circuits. As a result, drug development efforts have pursued new targets in the search for safer and more effective drugs to treat schizophrenia and psychosis, such as trace amine-associated receptors (TAARs), muscarinic receptors, and serotonergic receptors.

Global schizophrenia drugs market is dominated by Asia pacific region. Many manufacturers on the market are concentrating on research and development efforts to create safer and more effective medications to treat mental disorders. Key players are also attempting to enter into agreements, colorations, and acquisitions to broaden their product range in order to meet the soaring demand for anti-anxiety and anti-depression medications.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Schizophrenia Drugs Market

Report ID: UCMIG35I2123 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

Insomnia Therapeutics Market
Buy Now GET FREE SAMPLE
Global Schizophrenia Drugs Market

Report ID: SQMIG35I2317 | Region: Global | Published Date: April, 2024 | Pages: 219 | Tables: 65 | Figures: 80

Global Liver Health Supplements Market
Buy Now GET FREE SAMPLE
Global Schizophrenia Drugs Market

Report ID: UCMIG35I2009 | Region: Global | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

HVAC Filters Market
Buy Now GET FREE SAMPLE
Global Schizophrenia Drugs Market

Report ID: UCMIR35I2289 | Region: Regional | Published Date: April, 2024 | Pages: 165 | Tables: Figures:

Asia Pacific Human Insulin Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Schizophrenia Drugs Market

Product ID: SQSG35I2011

$5,300
BUY NOW GET FREE SAMPLE